Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy



Status:Recruiting
Conditions:Lung Cancer, Lung Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/7/2019
Start Date:January 23, 2019
End Date:August 19, 2021
Contact:Novartis Pharmaceuticals
Email:novartis.email@novartis.com
Phone:1-888-669-6682

Use our guide to learn which trials are right for you!

A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Canakinumab in Combination With Docetaxel Versus Placebo in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancer (NSCLC) Previously Treated With PD-(L)1 Inhibitors and Platinum-based Chemotherapy (CANOPY 2)

This phase III study is designed to evaluate the role of IL-1β inhibition in combination with
docetaxel in subjects with advanced NSCLC previously treated with PD-(L)1 inhibitors and
platinum-based chemotherapy. The randomized III part will be preceded by a safety run-in part
in which the recommended dose of the combination of canakinumab and docetaxel will be
confirmed.


Key Inclusion Criteria:

- Histologically confirmed advanced (stage IIIB) or metastatic NSCLC.

- Subject has received one prior platinum-based chemotherapy and one prior PD-(L)1
inhibitor therapy for locally advanced or metastatic disease.

- Subject with ECOG performance status (PS) of 0 or 1.

- Subject with at least 1 evaluable (measurable or non-measurable) lesion by RECIST 1.1
in solid tumors criteria.

Key Exclusion Criteria:

- Subject who previously received docetaxel, canakinumab (or another IL-1β inhibitor),
or any systemic therapy for their locally advanced or metastatic NSCLC other than one
platinum-based chemotherapy and one prior PD-(L)1 inhibitor.

- Subject with EGFRor ALK positive tumor.

- History of severe hypersensitivity reaction to monoclonal antibodies, taxanes or
excipients of docetaxel or canakinumab.

Other protocol-defined inclusion/exclusion may apply.
We found this trial at
2
sites
?
mi
from
Bruxelles,
Click here to add this to my saved trials
Loma Linda, California
Principal Investigator: Hamid R. Mirshahidi
Phone: 909-558-8683
?
mi
from
Loma Linda, CA
Click here to add this to my saved trials